Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

FENC

Fennec Pharmaceuticals Inc

Dec 05 • 04:00PM ET

7.55

-0.23 -2.96 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX BMRN ALNY SRPT AGEN XOMA ACAD NBIX PRQR IONS

| Held by: VTI IWM IWN VTWO IWC IWO VTWV RSSL VTWG OMFS

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.24	Insider Own	25.87%	Shs Outstand	34.14M	Perf Week	-7.81%
Market Cap	257.76M	Forward P/E	10.62	EPS next Y	0.71	Insider Trans	-4.28%	Shs Float	28.57M	Perf Month	-8.48%
Enterprise Value	253.92M	PEG	-	EPS next Q	0.03	Inst Own	50.19%	Short Float	3.76%	Perf Quarter	-16.30%
Income	-6.57M	P/S	6.64	EPS this Y	-	Inst Trans	0.91%	Short Ratio	9.37	Perf Half Y	-10.44%
Sales	38.79M	P/B	-	EPS next Y	598.13%	ROA	-12.15%	Short Interest	1.07M	Perf YTD	19.46%
Book/sh	-0.16	P/C	11.74	EPS next 5Y	-	ROE	-	52W High	9.92 -23.89%	Perf Year	21.19%
Cash/sh	0.64	P/FCF	-	EPS past 3/5Y	71.16% 52.21%	ROIC	-48.29%	52W Low	4.68 61.32%	Perf 3Y	-22.64%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	93.12%	Volatility	5.33% 6.52%	Perf 5Y	-3.45%
Dividend TTM	-	EV/Sales	6.55	EPS Y/Y TTM	-521.41%	Oper. Margin	-12.02%	ATR (14)	0.47	Perf 10Y	249.54%
Dividend Ex-Date	-	Quick Ratio	4.44	Sales Y/Y TTM	-21.39%	Profit Margin	-16.95%	RSI (14)	41.52	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.69	EPS Q/Q	89.07%	SMA20	-4.61%	Beta	0.77	Target Price	15.00
Payout	-	Debt/Eq	-	Sales Q/Q	78.69%	SMA50	-10.68%	Rel Volume	0.62	Prev Close	7.78
Employees	32	LT Debt/Eq	-	Earnings	Nov 13 AMC	SMA200	-2.65%	Avg Volume	114.64K	Price	7.55
IPO	Oct 22, 2003	Option/Short	Yes / Yes	EPS/Sales Surpr.	9.09% 11.30%	Trades		Volume	71,118	Change	-2.96%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-22-22	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$9 → $12
Sep-07-22	Initiated	CapitalOne	Overweight	$11
Aug-08-22	Resumed	Craig Hallum	Buy	$14
Jun-05-20	Initiated	Cantor Fitzgerald	Overweight	$18
Oct-11-18	Initiated	Goldman	Buy

Dec-02-25 07:01AM	Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK in Japan to Reduce Cisplatin-Induced Hearing Loss (GlobeNewswire)
Nov-26-25 05:59AM	Fennec Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-19-25 07:03AM	Fennec Pharmaceuticals Announces Completion Of Full Debt Redemption (GlobeNewswire) -6.51%
Nov-18-25 08:30AM	Fennec Pharmaceuticals Announces Closing of Private Offering of Common Shares in Canada (GlobeNewswire)
Nov-17-25 04:15PM	Fennec Pharmaceuticals Announces Closing of Offering of Common Shares (GlobeNewswire) +11.32%
11:11PM	Loading…
Nov-13-25 11:11PM	Fennec Pharmaceuticals Announces Private Offering of Common Shares in Canada (GlobeNewswire)
11:07PM	Fennec Pharmaceuticals Announces Pricing of Offering of Common Shares (GlobeNewswire)
05:10PM	Adherex Technologies Inc. (FENC) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:08PM	Fennec Pharmaceuticals Announces Proposed Offering of Common Shares (GlobeNewswire)
04:01PM	Fennec Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Nov-12-25 05:25PM	Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
Nov-04-25 06:00PM	Niagen Bioscience (NAGE) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
Oct-30-25 10:00AM	Adherex Technologies Inc. (FENC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Oct-22-25 10:19AM	Are Options Traders Betting on a Big Move in Fennec Pharmaceuticals Stock? (Zacks)
Oct-15-25 04:20AM	New Strong Sell Stocks for Oct. 15th (Zacks) +5.86%
09:40AM	Loading…
Oct-06-25 09:40AM	Day One Biopharmaceuticals (DAWN) Moves 7.0% Higher: Will This Strength Last? (Zacks)
Sep-19-25 09:43AM	Is the Options Market Predicting a Spike in Adherex Technologies Stock? (Zacks)
Aug-14-25 07:20AM	Adherex Technologies Inc. (FENC) Reports Q2 Loss, Beats Revenue Estimates (Zacks) -6.37%
06:08AM	Fennec Pharmaceuticals Reports Second Quarter 2025 Financial Results And Provides Business Update (GlobeNewswire)
Aug-13-25 05:15PM	Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Aug-12-25 05:10PM	Cue Biopharma, Inc. (CUE) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +12.00%
Aug-11-25 08:15AM	Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:12AM	Fennec Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 14, 2025 (GlobeNewswire)
Aug-07-25 07:05PM	Concentra Group (CON) Matches Q2 Earnings Estimates (Zacks)
Jul-31-25 09:40AM	Are Medical Stocks Lagging Editas Medicine (EDIT) This Year? (Zacks)
Jul-15-25 08:50AM	Recent Price Trend in Adherex Technologies (FENC) is Your Friend, Here's Why (Zacks)
Jun-03-25 04:31PM	Fennec Announces Results of Annual Meeting (GlobeNewswire)
May-14-25 10:51AM	The Joint Misses Q1 Earnings Estimates on Rising Expenses (Zacks)
03:07AM	Fennec Pharmaceuticals Inc (FENC) Q1 2025 Earnings Call Highlights: Strong Sales Growth Amid ... (GuruFocus.com)
May-13-25 11:33PM	Q1 2025 Fennec Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
11:06AM	Loading…
11:06AM	Acadia Healthcare Q1 Earnings Top Estimates on Rising Admissions (Zacks)
07:15AM	Adherex Technologies Inc. (FENC) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
06:03AM	Fennec Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-12-25 05:10PM	Cue Biopharma, Inc. (CUE) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +5.38%
May-09-25 06:26PM	Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates (Revised) (Zacks)
May-08-25 06:05PM	AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:17PM	Fennec Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025 (GlobeNewswire)
May-07-25 05:35PM	Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates (Zacks)
Apr-30-25 09:55AM	Wall Street Analysts See an 113.25% Upside in Adherex Technologies (FENC): Can the Stock Really Move This High? (Zacks)
Apr-10-25 09:35AM	Down -22.15% in 4 Weeks, Here's Why Adherex Technologies (FENC) Looks Ripe for a Turnaround (Zacks)
Mar-21-25 10:21AM	Immunocore (IMCR) Moves 6.0% Higher: Will This Strength Last? (Zacks)
Mar-11-25 03:00AM	Fennec Pharmaceuticals Inc (FENC) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
12:31AM	Q4 2024 Fennec Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-10-25 06:03AM	Fennec Pharmaceuticals Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update (GlobeNewswire) -11.19%
Mar-06-25 04:22PM	Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2024 Financial Results on March 10, 2025 (GlobeNewswire)
Feb-07-25 07:00AM	Fennec Pharmaceuticals Announces Commercial Launch of PEDMARQSI In Germany (GlobeNewswire)
Dec-20-24 06:16AM	Fennec Pharmaceuticals Announces Pedmarqsi Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales (GlobeNewswire)
Dec-19-24 06:13AM	Fennec Pharmaceuticals Announces Early Partial Repayment of Its Outstanding Convertible Debt Facility with Petrichor Healthcare Capital Management (GlobeNewswire)
Dec-12-24 07:01AM	Fennec Pharmaceuticals to Participate in Upcoming Investor Conference (GlobeNewswire)
Nov-13-24 06:27AM	Fennec Pharmaceuticals to Participate in Upcoming Investor Conference (GlobeNewswire) +5.91%
Nov-09-24 02:00AM	Fennec Pharmaceuticals Inc (FENC) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com)
Nov-07-24 06:13AM	Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -11.92%
Oct-31-24 06:23AM	Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024 (GlobeNewswire)
Oct-28-24 06:23AM	Fennec Pharmaceuticals Strengthens Executive Leadership Team with Three Key Appointments to Accelerate the Company's Next Stage of Growth (GlobeNewswire) +11.56%
Sep-05-24 06:56AM	Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-14-24 01:57AM	Q2 2024 Fennec Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -8.89%
Aug-13-24 06:05AM	Fennec Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -6.40%
Aug-06-24 04:31PM	Fennec Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 13, 2024 (GlobeNewswire)
Aug-05-24 06:26AM	Fennec Pharmaceuticals Appoints Jeffrey S. Hackman as Chief Executive Officer and Director (GlobeNewswire)
Jul-29-24 06:15AM	3 Dirt-Cheap Stocks Under $10 That Could EXPLODE! (InvestorPlace)
Jul-15-24 08:32AM	Implied Volatility Surging for Fennec (FENC) Stock Options (Zacks)
Jul-01-24 06:00AM	Fennec Pharmaceuticals Announces Management Change (GlobeNewswire)
Jun-25-24 04:35PM	Fennec Announces Results of Annual Meeting (GlobeNewswire)
May-15-24 08:44AM	HC Wainwright Adjusts Fennec Pharmaceuticals Price Target to $15 From $18, Maintains Buy Rating (MT Newswires)
May-14-24 10:53AM	FENC Stock Earnings: Fennec Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) -26.75%
07:20AM	Fennec Pharmaceuticals Swings to Q1 Profit on Higher Sales, Licensing Revenue (MT Newswires)
06:03AM	Fennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-07-24 06:15PM	Fennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024 (GlobeNewswire)
Apr-23-24 08:01AM	Fennec Pharmaceuticals Insider Sold Shares Worth $414,472, According to a Recent SEC Filing (MT Newswires)
Apr-05-24 07:00PM	Insider Sell: CEO Rosty Raykov Sells 88,583 Shares of Fennec Pharmaceuticals Inc (FENC) (GuruFocus.com)
Mar-27-24 07:00PM	Chief Financial Officer Robert Andrade Sells 13,975 Shares of Fennec Pharmaceuticals Inc (FENC) (GuruFocus.com)
Mar-26-24 01:00AM	Chief Financial Officer Robert Andrade Sells Shares of Fennec Pharmaceuticals Inc (FENC) (GuruFocus.com)
Mar-22-24 09:49AM	Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q4 2023 Earnings Call Transcript (Insider Monkey)
05:04AM	Q4 2023 Fennec Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-21-24 02:52PM	FENC Stock Earnings: Fennec Pharmaceuticals Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace)
06:00AM	Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-19-24 10:14AM	Fennec (FENC) Signs Licensing Deal With Norgine, Stock Up (Zacks)
06:01AM	Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024 (GlobeNewswire)
Mar-17-24 09:00PM	Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand (GlobeNewswire)
Feb-29-24 07:04AM	Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results (GlobeNewswire)
Feb-01-24 05:55AM	FDA Issues Reminder of Non-Substitution of PEDMARK® (sodium thiosulfate injection) for Pediatric Patients Receiving Cisplatin (GlobeNewswire)
Jan-06-24 03:01AM	Insider Sell: CFO Robert Andrade Sells 30,000 Shares of Fennec Pharmaceuticals Inc (GuruFocus.com)
Dec-05-23 05:55AM	Fennec Announces Incremental $5 Million Investment from Petrichor (GlobeNewswire)
Nov-09-23 04:50PM	Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-07-23 09:40AM	Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q3 2023 Earnings Call Transcript (Insider Monkey)
02:10AM	Q3 2023 Fennec Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-06-23 05:59AM	Fennec Pharmaceuticals Announces Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +15.36%
Oct-30-23 06:45AM	Fennec Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 6, 2023 (GlobeNewswire)
Sep-07-23 05:59AM	Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-10-23 12:53PM	Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-03-23 05:59AM	Fennec Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) -7.29%
Jul-31-23 05:30AM	Fennec Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 3, 2023 (GlobeNewswire) +8.66%
Jun-12-23 05:00PM	Fennec Announces Results of Annual Meeting (GlobeNewswire)
Jun-08-23 02:53PM	Retail investors who hold 38% of Fennec Pharmaceuticals Inc. (NASDAQ:FENC) gained 13%, institutions profited as well (Simply Wall St.)
Jun-06-23 05:44AM	Fennec Pharmaceuticals Announces European Commission Marketing Authorization for Pedmarqsi (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients (GlobeNewswire)
May-11-23 06:01AM	Fennec Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
May-08-23 06:15AM	Fennec Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023 (GlobeNewswire)
Apr-28-23 09:26AM	When Will Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Become Profitable? (Simply Wall St.)
Apr-01-23 08:12AM	Investors in Fennec Pharmaceuticals (NASDAQ:FENC) have made a notable return of 52% over the past three years (Simply Wall St.)
Mar-31-23 08:03AM	Fennec Pharmaceuticals Receives Positive CHMP Opinion for Pedmarqsi (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients (GlobeNewswire)

Fennec Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on the development and commercialization of PEDMARK to reduce the risk of platinum-induced ototoxicity in pediatric patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Raykov Rosty	Director	Dec 05 '25	Sale	7.54	10,000	75,400	77,526	Dec 05 06:41 PM
ROSTISLAV RAYKOV	Director	Dec 05 '25	Proposed Sale	7.54	10,000	75,444		Dec 05 05:13 PM
Southpoint Capital Advisors LP	10% Owner	Nov 18 '25	Sale	8.79	19,341	170,048	3,744,741	Nov 20 04:07 PM
Southpoint Capital Advisors LP	10% Owner	Nov 14 '25	Sale	8.00	160,100	1,280,432	3,850,000	Nov 17 08:42 PM
Southpoint Capital Advisors LP	10% Owner	Nov 17 '25	Sale	8.79	85,918	755,193	3,764,082	Nov 17 08:42 PM
Raykov Rosty	Director	Nov 05 '25	Sale	8.10	10,000	81,000	82,318	Nov 06 04:10 PM
ROSTISLAV RAYKOV	Director	Nov 05 '25	Proposed Sale	8.11	10,000	81,082		Nov 05 04:28 PM
RALLIS CHRIS A	Director	Oct 10 '25	Option Exercise	1.23	4,062	4,996	58,854	Oct 14 04:10 PM
RALLIS CHRIS A	Director	Oct 10 '25	Sale	9.24	1,775	16,401	57,079	Oct 14 04:10 PM
CHRIS A RALLIS	Director	Oct 10 '25	Proposed Sale	9.24	1,775	16,401		Oct 10 04:02 PM
Southpoint Capital Advisors LP	10% Owner	Oct 07 '25	Sale	9.59	26,900	257,893	4,050,314	Oct 09 05:31 PM
Southpoint Capital Advisors LP	10% Owner	Oct 09 '25	Sale	9.35	20,609	192,614	4,010,100	Oct 09 05:31 PM
Southpoint Capital Advisors LP	10% Owner	Oct 08 '25	Sale	9.47	19,605	185,722	4,030,709	Oct 09 05:31 PM
Raykov Rosty	Director	Oct 08 '25	Option Exercise	2.45	4,609	11,292	87,110	Oct 08 05:08 PM
Raykov Rosty	Director	Oct 06 '25	Sale	9.78	10,000	97,800	82,501	Oct 06 06:22 PM
ROSTISLAV RAYKOV	Director	Oct 06 '25	Proposed Sale	9.79	10,000	97,868		Oct 06 04:27 PM
Raykov Rosty	Director	Sep 05 '25	Option Exercise	2.45	36,207	88,707	87,293	Sep 08 06:05 PM
ROSTISLAV RAYKOV	Director	Sep 04 '25	Proposed Sale	8.92	10,000	89,220		Sep 04 04:37 PM
Raykov Rosty	Director	Sep 04 '25	Sale	8.92	10,000	89,200	51,086	Sep 04 04:10 PM
Raykov Rosty	Director	Aug 05 '25	Sale	8.09	10,000	80,900	55,878	Aug 05 05:33 PM
ROSTISLAV RAYKOV	Director	Aug 05 '25	Proposed Sale	8.09	10,000	80,933		Aug 05 04:14 PM
RALLIS CHRIS A	Director	Jul 07 '25	Option Exercise	2.35	2,127	4,998	55,911	Jul 07 05:31 PM
RALLIS CHRIS A	Director	Jul 07 '25	Sale	8.71	1,119	9,746	54,792	Jul 07 05:31 PM
Raykov Rosty	Director	Jul 03 '25	Sale	8.61	10,000	86,100	60,670	Jul 07 04:30 PM
ROSTISLAV RAYKOV	Director	Jul 03 '25	Proposed Sale	8.61	10,000	86,102		Jul 03 02:01 PM
Raykov Rosty	Director	Jun 05 '25	Sale	7.78	10,000	77,800	65,462	Jun 06 04:20 PM
ROSTISLAV RAYKOV	Director	Jun 05 '25	Proposed Sale	7.78	10,000	77,781		Jun 05 04:31 PM
Andrade Robert	CHIEF FINANCIAL OFFICER	May 22 '25	Option Exercise	5.10	8,220	41,922	158,520	May 23 04:20 PM
Hackman Jeffrey S.	Chief Executive Officer	May 19 '25	Buy	6.99	13,965	97,615	15,000	May 19 05:42 PM
Hackman Jeffrey S.	Chief Executive Officer	May 16 '25	Buy	6.75	1,035	6,986	1,035	May 19 05:42 PM
Raykov Rosty	Director	May 16 '25	Sale	6.78	16,667	113,002	70,254	May 19 04:30 PM
Raykov Rosty	Director	May 16 '25	Proposed Sale	6.01	16,667	100,169		May 16 05:21 PM
Raykov Rosty	Director	May 05 '25	Sale	6.31	10,000	63,100	53,587	May 05 06:23 PM
ROSTISLAV RAYKOV	Director	May 05 '25	Proposed Sale	6.31	10,000	63,078		May 05 04:01 PM
Raykov Rosty	Director	Apr 04 '25	Sale	5.25	10,000	52,500	61,156	Apr 04 07:29 PM
ROSTISLAV RAYKOV	Director	Apr 04 '25	Proposed Sale	5.25	10,000	52,537		Apr 04 04:12 PM
Raykov Rosty	Director	Mar 05 '25	Sale	6.79	10,000	67,900	68,725	Mar 06 05:32 PM
ROSTISLAV RAYKOV	Director	Mar 05 '25	Proposed Sale	6.79	10,000	67,930		Mar 05 04:29 PM
RALLIS CHRIS A	Director	Feb 14 '25	Option Exercise	2.51	1,992	5,000	54,206	Feb 14 06:13 PM
RALLIS CHRIS A	Director	Feb 14 '25	Sale	6.82	1,186	8,089	53,020	Feb 14 06:13 PM
CHRIS A RALLIS	Director	Feb 14 '25	Proposed Sale	6.82	1,186	8,089		Feb 14 04:03 PM
Raykov Rosty	Director	Feb 05 '25	Sale	6.66	10,000	66,600	76,294	Feb 05 08:24 PM
ROSTISLAV RAYKOV	Director	Feb 05 '25	Proposed Sale	6.66	10,000	66,558		Feb 05 04:42 PM
Raykov Rosty	Director	Jan 06 '25	Sale	6.08	10,000	60,800	83,863	Jan 07 05:15 PM
ROSTISLAV RAYKOV	Director	Jan 06 '25	Proposed Sale	6.08	10,000	60,847		Jan 06 04:19 PM
Raykov Rosty	Director	Dec 20 '24	Option Exercise	2.69	25,000	67,250	91,432	Dec 23 05:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

FENC

Fennec Pharmaceuticals Inc

Upgrade your FINVIZ experience